investigated beta carotene or carotenoids, the other drugs tested were bleomycin (one study), mixed tea (one study) and ketorolac (one study). One study tested two treatments. Malignant transformation was recorded in just two studies: none of the treatments tested showed a benefit when compared with the placebo. Treatment with beta carotene, lycopene and vitamin A or retinoids, was associated with significant rates of clinical resolution, compared with placebo or absence of treatment. Whenever reported, a high rate of relapse was a common finding. Side effects of variable severity were often described; however, interventions were well accepted by patients, since drop-out rates were similar between treatment and control groups.
Authors' conclusions
To date there is no evidence of effective treatment in preventing malignant transformation of leukoplakia. Treatments may be effective in the resolution of lesion, however relapses and adverse effects are common.
P L A I N L A N G U A G E S U M M A R Y

Interventions for treating oral leukoplakia
No evidence from trials to show how to prevent leukoplakia in the mouth becoming malignant.
Oral leukoplakia is a thickened white patch formed in the mouth lining that cannot be rubbed off. Leukoplakia is a lesion that sometimes becomes cancerous (a tumour that invades and destroys tissue, then spreads to other areas). Preventing this change is critical as survival rates of more than 5 years after diagnosis with oral cancer is low. Drugs, surgery and other therapies have been tried. The review of trials compared several drugs such as bleomycin, vitamin A and beta carotene supplements and mixed tea. There was no evidence found to show the effects of these treatments. More research is needed.
B A C K G R O U N D
"Oral leukoplakia is a predominantly white lesion of the oral mucosa that cannot be characterised as any other definable lesion" ( Axell 1996) . Such a definition, also adopted by the World Health Organization (WHO), is the result of the effort of an international group of experts, who met in Uppsala in 1994 in order to review leukoplakia definitions and classifications on the basis of previously published work (Axell 1984; Kramer 1978) and new scientific acquisitions. Thus, leukoplakia is a clinical term used when any other white oral lesion has been excluded. Leukoplakia is often associated with tobacco smoking, although idiopathic forms are not rare (Axell 1987) . The role of alcohol, viruses and systemic conditions need further investigations (Campisi 2004; Dietrich 2004) .
Clinical variants of leukoplakia are classified into two groups: (1) homogeneous leukoplakia, a lesion of uniform flat appearance that may exhibit superficial irregularities, but with consistent texture throughout ( Figure 1) ; (2) non-homogeneous leukoplakia, a predominantly white or white and red lesion (erythroleukoplakia) with an irregular texture that may be characterised by a flat, nodular or exophytic aspect (Figure 2 ). Histological features of both forms of leukoplakia are quite variable and may include ortho-or para-keratosis of various degrees, mild inflammation and dysplastic changes of various degrees. Leukoplakia is not uncommon. Although highly variable among geographical areas and demographical groups, the prevalence of leukoplakia in the general population varies from less than 1% to more than 5% (Axell 1984; Axell 1987; Bouquot 1986; Ikeda 1991; Reichart 2000) . In a recent systematic review, when studies with more than 1000 individuals were included, prevalence varied between 0.50% and 3.46%, and the pooled prevalence estimated was between 1.49% and 4.27% (Petti 2003) . Incidence data are very scarce, a recent study from Japan reported an age-adjusted incidence rate per 100,000 persons-years of 409.2 among males and 70 among females (Nagao 2005) , while an Indian study, conducted in a population with distinctive risk factors for oral cancer, reported lower figures: 240 among males and 3 among females ( Gupta 1980) . Leukoplakia is a precancerous lesion, i.e. "a morphologically altered tissue in which cancer is more likely to occur than in its apparently normal counterpart" (Axell 1996) . The rate of malignant transformation into squamous cell carcinoma varies from almost 0% to about 20% in 1 to 30 years (Lind 1987; Schepman 1998; Silverman 1984) . Recently, a study investigating the natural limit of leukoplakia malignant transformation on the basis of European epidemiological data, concluded that the upper limit of the annual transformation rate of oral leukoplakia is unlikely to exceed 1% (  Scheifele 2003) . Non-homogeneous leukoplakias carry a higher degree of risk of transformation when compared with the homogeneous variants. Patients with signs of dysplasia, about 1/10 of the total, may be at a higher risk. However, studies investigating biomarkers and histological features have found no reliable method to identify which lesion will undergo malignant transformation and which will not (Warnakulasuriya 2000) . Clinical (Zhang 2005) , histological (Lee 2000) and molecular markers (Zhang 2001) may contribute in assessing the risk of a single patient to develop cancer, however a single, evidence-based and clinically useful predictor of malignant transformation for dysplastic and non-dysplastic leukoplakias, is not available at the moment. Since most leukoplakias are asymptomatic, the need for treatment is primarily based on the precancerous nature of the lesion. Prevention of malignant transformation is particularly important in view of the poor prognosis associated with oral squamous cell carcinoma, with only 30% to 40% of patients still alive 5 years after the diagnosis (Scully 2000). Many treatments have been proposed for oral leukoplakias (including medical and surgical therapies).
O B J E C T I V E S
To compare the outcomes for patients affected by oral leukoplakia, undergoing medical or surgical treatments or both compared with placebo or no treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-randomised controlled trials were included.
Types of participants
Anyone with a diagnosis of oral leukoplakia as defined, at the time of the studies, by the consensus conferences held in 1978 , 1983 , 1994 (Axell 1984 Axell 1996; Kramer 1978) .
Types of interventions
Active
• Surgical removal of the lesion, including surgical excision, laser surgery, cryotherapy.
• Topical medical treatment, including anti-inflammatory agents, antimycotic agents, carotenoids and retinoids, cytotoxic agents, etc..
• Systemic medical treatment.
• Removal of predisposing habits (e.g. tobacco, alcohol, etc.).
• Other treatment (e.g. photodynamic therapy).
• Combined treatment.
Control
• Placebo.
• No treatment.
Types of outcome measures Primary outcomes
Because of the precancerous nature of leukoplakia, the primary objective of treatment is to prevent malignant transformation. Thus leukoplakia morbidity, in terms of frequency of malignant transformation, demonstrated by histopathological examination, was the main outcome considered.
Secondary outcomes
As epithelial dysplasia may already be present at the time of diagnosis, variation in histological features was also included in the outcome measures. For interventions directed toward elimination of the lesion, especially by surgical methods, long term resolution and proportion of relapsing lesions were considered. Outcome measures included safety and acceptability of the intervention, as measured by the incidence of adverse effects and proportion of patients dropping out respectively. Sensitive search strategies were developed for each database (available from the review authors on request) using a combination of free text and MeSH terms such as leukoplakia, oral precancer, oral preneoplastic lesion. The search strategy for CENTRAL is given as an example in Appendix 1. The metaRegister of Controlled Trials was searched for relevant trials (www.controlled-trials.com). Language: studies in all languages were considered for translation. Reference lists of included studies and existing reviews were checked. In order to detect unpublished and ongoing trials, a formal letter requesting information was sent to Oral Medicine experts by EU-RORALMED, an electronic mailing list reaching a vast number of colleagues, mainly from European countries. Pharmaceutical companies were also contacted. The following journals were identified as being important to be handsearched for the review: 
Search methods for identification of studies
• Cancer •
Data collection and analysis
The title and abstract of each article resulting from the different search strategies were examined separately by two review authors. When at least one review author considered the article relevant, it progressed in the review process and was included in a digital archive prepared using a dedicated software. Full reports were obtained for all relevant studies.
Critical appraisal of studies
Every study reporting a randomised or quasi-randomised clinical trial was assessed by two review authors according to the criteria for randomised trial data suggested by Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (Higgins 2005) and EvidenceBased Medicine. How to practice and teach EBM (Sackett 1997). In particular the study's validity was judged on the basis of.
• Method of allocation concealment. It was considered 'adequate' when the assignment of patients to treatments was randomised and the randomisation schedule was kept concealed to the researcher recruiting participants. When papers did not report such information, the criterion was considered 'unclear'.
• Protection against performance bias (blindness of the study). The criterion was considered 'met' when patients and researchers assessing outcome measures were kept 'blind', and 'partially met' when only one group (patients or researchers) was kept 'blind'. When blinding was not possible (as in surgical treatment) this criterion was not considered in the validity rating of the study.
• Losses of participants. At least 80% of patients who entered the trial should be included in the final analysis.
Each of these criteria was rated as 'met', 'partially met', 'unmet', or 'unclear'. The global validity of the study was assessed using three categories.
(1) Low risk of bias: all of the criteria met.
(2) Moderate risk of bias: one or more criteria partially met. (3) High risk of bias: one or more criteria unmet or unclear. The critical appraisal of the studies was carried out without blinding the name of authors, institutions and journal. Data about the study, its eligibility, validity, design and outcome information, were recorded by each reviewer on an extraction form. In case of disagreement, consensus was achieved by discussion and a new form was completed.
Statistical analyses
When valid and relevant data were collected, a meta-analysis of the data was undertaken. For each intervention, statistical analyses evaluated the available data on differences among effects in terms of morbidity (i.e. malignant changes), relapse (for interventions directed toward elimination of the lesion), adverse effects and patients dropping out.
The primary measure of intervention effect was reduction of morbidity, as indicated by the difference in incidence of malignant changes, between the control and intervention groups. Dichotomous data were expected for the main outcome measure (cancerization versus absence of cancerization). In case of variations in histological features, the data were dichotomised in decreased severity or no change in histological features versus getting worse. Other dichotomous data included, incidence of adverse effects and frequency of drop-out patients. For each intervention, data on the number of patients of intervention and control groups who experienced the event (outcome) and the total number of patients, were sought and summarised. Dichotomous data were analysed by calculating risk ratios. As we pooled together data from studies in which true treatment effects are likely to differ, a random-effects model has been used in the statistical analyses. Missing data were obtained from tables and graphs or by contacting the authors. Subgroup analysis was undertaken for class of drug (vitamin A and retinoids). Subgroup analyses for smoking and non-smoking patients, and for lesions with or without dysplasia, were not possible because such data were not available. A sensitivity analysis was undertaken, excluding studies of lower methodological quality (i.e. studies at high risk of bias).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies. We found only one randomised controlled trial (RCT) evaluating surgical interventions (Schwarz 2005), unfortunately it did not include a no treatment/placebo group, and for this reason it was excluded from the review (see Criteria for considering studies for this review). Twenty-five potentially eligible RCTs were identified: 11 were excluded (see Characteristics of excluded studies table) and five were ongoing studies (Beenken 2000; Boyle 2000; Chiang 2005; Goodin 2005; Lippman 2004) , leaving nine studies to be included in the review. Three of the included studies were a threearm trial (Gaeta 2000; Sankaranarayan 1997; Singh 2004) , but in two of them we pooled together the data of the active arms: in one case the two interventions differ only in lactose content (a putative non-active component) (Gaeta 2000) , in the other the interventions differ in dosage (Singh 2004) . Four RCTs compared topical treatment versus placebo (totaling 100 patients) (Epstein 1994; Gaeta 2000; Mulshine 2004; Piattelli 1999) , four RCTs compared systemic treatment versus placebo (totaling 327 patients) (Hong 1986; Sankaranarayan 1997; Singh 2004; Stich 1988) . One RCT compared an association of topical and systemic treatments with placebo (64 patients) (Li 1999). Vitamin A and retinoids were tested by five RCTs (245 patients) (Gaeta 2000; Hong 1986; Piattelli 1999; Sankaranarayan 1997; Stich 1988) , two studies investigated beta carotene (Sankaranarayan 1997) and a carotenoid (lycopene) ( Singh 2004 ). The other drugs tested were bleomycin (Epstein 1994), mixed tea (a mixture of whole water extract of green tea, green tea polyphenols, and tea pigments in the ratio of 4:1:1) ( Li 1999), and ketorolac (Mulshine 2004). The total number of patients of the included studies was 501. In all patients enrolled in the studies a biopsy had been taken to confirm the diagnosis of leukoplakia, however only two studies reported the histologic criteria used (Epstein 1994; Stich 1988) . Five studies reported the percentage of dysplastic lesions that varied from 20% to 59%. In one study dysplastic lesions were in the treatment arms but not in the control group (Gaeta 2000) . The reported proportion of smoking and drinking patients (the two main risk factors for oral cancer) varied from 30% to 86% and from 18% to 86%, respectively. None of the authors reported significant changes in these habits during the course of the trial. In two studies (Sankaranarayan 1997; Stich 1988 ) the totality of subjects recruited were chewers of tobacco-containing betel quid (another well known risk factor for oral cancer) from the same Indian village (Trivandrum, Kerala). The follow-up period since the end of treatment was reported in five RCTs (Epstein 1994; Hong 1986; Mulshine 2004; Sankaranarayan 1997; Singh 2004) , varying from 1 to 15 months. Only two studies reported useful data on cancer development ( Epstein 1994; Sankaranarayan 1997); in Epstein's trial only part of the placebo group was taken into account, as 7 out of 12 patients of this group received the active treatment at the end of the study period, and thus were excluded from the placebo group for this outcome. All the included studies reported clinical changes of leukoplakias. A complete response was defined as the complete disappearance of the lesion in seven RCTs; six of them had also the same definition for partial response (greater than 50% reduction), while one had slightly different criteria (greater than 30% reduction) ( Li 1999). One RCT categorised the response of leukoplakias into three groups (remission, no change, new leukoplakia) and another used a three value descriptive clinical scale, in both cases the criteria were not specified. Assessment of the histological modifications following the treatment was reported by four RCTs (Epstein 1994; Gaeta 2000; Hong 1986; Singh 2004) ; one RCT investigated some biomarkers of DNA damage and cell proliferation ( Li 1999), but the results of this study were not included as not comparable with the previous two. A further study reported histological changes in the treatment group only (Stich 1988).
Risk of bias in included studies
On the basis of the criteria used in the critical appraisal of the studies, two studies resulted in a low risk of bias (Epstein 1994; Hong 1986) . In both studies the methods of allocation concealment were adequate and reported in detail, and more than 80% of the patients who entered the study were included in the final analysis. Six randomised controlled trials (RCTs) were judged at moderate risk of bias (Gaeta 2000; Li 1999; Mulshine 2004; Piattelli 1999; Sankaranarayan 1997; Singh 2004) , one of them was a quasi-randomised trial, while in the other the methods of allocation concealment were not described. The remaining study (Stich 1988 ) was considered at high risk of bias because of the unclear method of allocation concealment and the absence of protection against performance bias (blindness of the study).
Effects of interventions Malignant transformation (Comparison 1, Outcome 1.1)
Results from two studies, including 172 patients, were available for the analyses (as one of the studies has a three-arm design, the control group is indicated twice in the plot). Three drugs were evaluated in these studies: topical bleomycin (Epstein 1994), systemic vitamin A (Sankaranarayan 1997) and systemic beta carotene ( Sankaranarayan 1997). None of the treatments in these studies showed a benefit when compared with the placebo.
Clinical resolution (Comparison 1, Outcome 1.2)
Data on complete resolution of the oral lesions were available from all the nine studies included in the review (501 patients). Three treatments (bleomycin, ketorolac and tea) were only assessed in single studies and these treatments showed no benefit when compared to the placebo/control group. Two studies (Sankaranarayan 1997; Singh 2004) showed a significant benefit for the systemic treatment with beta carotene or lycopene (a carotenoid) when compared to the control (risk ratio (RR) Random = 0.69; 95% confidence interval (CI) 0.54 to 0.88). Five studies investigated the effectiveness of vitamin A or retinoids ( Gaeta 2000; Hong 1986; Piattelli 1999; Sankaranarayan 1997; Stich 1988) and found a small but significant benefit (RR Random = 0.69; 95% CI 0.50 to 0.96). Two of these studies employed topical retinoids (Gaeta 2000; Piattelli 1999) . Among patients treated with topical bleomycin (Epstein 1994), two out of four patients with a complete response, for whom follow-up information was available, relapsed; the same happened for one out of two patients with a partial response and follow-up data. Sankaranarayanan's study reported that 14 out of 22 (64%) complete responders of the first arm and 8 out of 15 (54%) complete responders of the second arm developed recurrent lesions (no information was available regarding the three complete responders of the placebo group) (Sankaranarayan 1997). Relapses were also reported by Hong and colleagues: 9 out of 16 (56%) patients responding to treatment (partially or completely) relapsed (no information was available regarding the two partial responders of the placebo group) (Hong 1986). In Piattelli's study one out of five (20%) patients responding to the experimental treatment and one out of four (25%) patients responding to placebo relapsed ( Piattelli 1999) . No data on relapses were available for the other studies.
Histological changes
Histological changes were available from four studies (Epstein 1994; Gaeta 2000; Hong 1986; Singh 2004) , but comparison was possible only for three of them, in fact in Gaeta's study, the absence of dysplastic lesions in the control group made impossible a comparison. In the other three studies the histological aspect of oral lesions did not improve (i.e. was stable or got worse) more frequently with placebo than with active treatment, and the difference was significant when retinoic acid (RR 
Safety and acceptability
Frequency of adverse effects varied largely among studies. Topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A, topical acitretin (10 mg twice per day), mixed tea and lycopene did not cause any adverse effects. Topical bleomycin, systemic 13-cisretinoic acid (1 to 2 mg/kg/day), ketorolac oral rinse, vitamin A (300,000 IU per week) and beta carotene (360 mg/week), caused adverse effects of various severity in 100%, 79%, 29%, 26% and 9% of patients, respectively (Table 1 ). Whenever present, adverse effects were always more common in the study group than in the control group. Adverse effects caused patients to withdraw in two studies only: when systemic 13-cis-retinoic acid induced severe conjunctivitis and hypertrigliceridemia and following an intolerable mouth pain following first ketorolac mouthrinse. Information on the reasons for patient withdrawal were missing in five out of six studies that reported at least one missing patient. In spite of adverse effects, treatment acceptability was good, as drop-out rates between treatments and placebo were similar in all but one study (Table 2) . 
D I S C U S S I O N
Leukoplakia is the most common precancerous oral lesion. Although rates of malignant transformation may vary among studies, probably due to differences in diagnostic criteria and followup intervals, the morbidity and mortality associated with oral cancer make leukoplakia a serious health problem. Nevertheless, we found only nine studies to include in the present review, none of these evaluated a surgical intervention. They showed little evidence for an effective treatment in the prevention of malignant transformation. There was some evidence that vitamin A, retinoids, beta carotene and lycopene may completely resolve the oral lesions, and that retinoic acid and lycopene may promote histological improvement, although this last result is only based on a small number of patients.
Less than half (33% to 42%) of leukoplakias which undergo malignant change, does so within 2 years of diagnosis (Lind 1987; Silverman 1984) and the incidence of malignant transformation increases with the duration of follow up (Shiu 2000). Therefore, in order to properly assess modifications in the rates of leukoplakia malignant transformation, it would be necessary to plan studies with large groups of patients and a long follow up: that means multicentre randomised controlled trials (RCTs). However, the mean follow up of the studies included in the review was no longer than 15 months, thus the transformation rates could be underestimated. Besides, some researchers used outcomes different from cancer development, in particular various cytological or histological markers or both. Although easier to perform, studies using such outcomes pose a double problem: first there is little evidence of the predictive value of many of those outcomes; second, they are hardly comparable. In addition, widespread outcomes such as dysplasia grade, may be affected by high observer variation (Abbey 1995; Karabulut 1995) . The applicability of the results of two of the studies included (Sankaranarayan 1997; Stich 1988) should be considered very carefully; in fact the patients included in those studies were all betel chewers, a risk factor not common in individuals from geographical areas outside the Indian subcontinent.
Leukoplakias with different histological or molecular characteristics may have different risks of turning into a cancer. However the value of the prognostic factors proposed so far in the literature still need sound confirmatory data. The presence of epithelial dysplasia may be predictive of a transformation to oral cancer and the risk of cancer incidence may increase with the severity of dysplastic changes (Lumerman 1995; Schepman 1998), although this hypothesis has been recently challenged (Holmstrup 2006) . Unfortunately the data available did not allow us to perform a subgroup analysis of lesions with and without dysplasia, thus it is not possible to establish if any particular treatment may be more indicated in the presence of dysplasia of different severity. Many different molecular biomarkers have been proposed, still no one seems convincing enough to be applied to clinical routine. Recently, studies on a very promising prognostic marker, cited in the previous version of this review, are being investigated for accuracy (Curfman 2006), following a case of scientific fraud (Horton 2006).
Leukoplakias are not morbid or lethal by themselves and have a relatively low risk of transformation. As a consequence many subjects receiving treatments have lesions that will never progress to cancer. For this reason proposed treatments should have minimal adverse effects in terms of incidence and severity. This is not the case for some of the interventions evaluated. In particular, high doses of retinoids may cause toxic effects severe enough to cause patients to stop treatment. However, in all but one trial the number of patients leaving the study group was not much bigger than the number of those leaving the placebo group (and in one study it was bigger in patients taking the placebo arm than in the two treatment arms).
It is noteworthy the absence of RCTs comparing the effects of surgical excision versus no treatment or placebo, surgery being the first choice in leukoplakia management for many clinicians ( Marley 1998). The only data available are from follow-up studies comparing rates of malignant transformation in patients who did and did not undergo surgical treatment of oral leukoplakias. Although results from such studies are hardly comparable because of differences in diagnostic and inclusion criteria, follow-up interval, patient characteristics and surgical techniques employed (scalpel, laser, cryotherapy), they show highly variable results and sometimes are conflicting in the conclusions (Saito 2001; Schepman 1998).
Trials evaluating interventions directed against risk factors (i.e. smoking) are also missing.
A U T H O R S ' C O N C L U S I O N S Implications for practice
None of the treatments studied was shown to be effective in preventing malignant transformation of leukoplakias.
Some treatments were effective in healing oral leukoplakia, however they did not seem able to prevent relapses and malignant change. For this reason the clinical healing of leukoplakia following one of these treatments, does not release the clinician from the duty of regular follow up.
Implications for research
Although surgery remains the first option for most clinicians, the real effectiveness of such treatment cannot be assessed, as it was not possible to find any randomised controlled trials of surgery versus no treatment (wait and see) in the prevention of malignant transformation of leukoplakia, the only randomised controlled trial comparing two laser techniques. Research is needed to assess surgery in the treatment of leukoplakia.
Until definitive evidence on the predictive value of specific biomarkers becomes available, malignant transformation should be considered the best outcome to take into account in testing the effectiveness of treatments for leukoplakia.
More research is needed to evaluate the effects of risk factor cessation on the malignant transformation of leukoplakia.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Epstein 1994
Methods Randomised, parallel-group, double-blind, clinical trial. Low risk of bias (RCT, double-blind, 100% of patients who entered the study were included in the final analysis). Outcomes Measurement of the lesion and recording of signs and symptoms, before starting the treatment and weekly during treatment. Complete response was defined as no clinical and histological evidence of leukoplakia. Partial response was defined as a greater than 50% reduction in the size of lesion or elimination of dysplasia. Assessment of oral burning and pain during application, between applications and with eating. Histological grading before starting treatment and 4 weeks following treatment.
Notes
Following the post-treatment biopsy 7 patients of the placebo group were crossed over to receive 1% w/v bleomycin in dimethylsulphoxide.
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Yes A -Adequate
Gaeta 2000
Methods Quasi-randomised, parallel-group, double-blind, 3 arms clinical trial. Moderate risk of bias (quasi-RCT, double-blind, 100% of patients who entered the study were included in the final analysis). Study duration: 4 weeks. Participants 21 patients: 5 females, mean age 52.5 (range 42 to 73), ethnic group not reported, tobacco users not reported, alcohol users not reported. Inclusion criteria: patients with histologically confirmed oral leukoplakia. Exclusion criteria: leukoplakia with severe dysplasia, impaired renal or hepatic functions, severe cardiological disease, woman in child bearing age. Histological criteria for leukoplakia: not reported. 29% of the lesions were dysplastic, but they were all in the treatments arms.
Gaeta 2000 (Continued)
Interventions 2 daily topical application of a mucoadhesive slow release tablet for 4 weeks. The 3 groups received tablets with: (A) acitretin 10 mg in methocel E5 55mg or (B) acitretin 10 mg in methocel E5 33 mg and lactose 23 mg (C) methocel E5 33 mg and lactose 23 mg (placebo). Compliance control: yes.
Outcomes Clinical and histological grading was done before starting treatment and upon its completion. At baseline and on the 28th day of treatment: assessment of the lesion according to a descriptive clinical scale (0 = no evidence of disease, 1 = mild involvement, 2 = moderate involvement, 3 = severe involvement).
Notes
The 2 treatment arms have been pooled together in the meta-analysis.
Risk of bias
Item
Authors' judgement Description
Allocation concealment? Unclear B -Unclear
Hong 1986
Methods Randomised, parallel-group, double-blind, clinical trial. Low risk of bias (RCT, double-blind, 90% of patients who entered the study were included in the final analysis). Study duration: 9 months. Participants 44 patients: 13 females; age groups: < 50 years: 9 patients, 50 to 69 years: 29 patients, > 70 years: 6 patients; ethnic group not reported; 9 (20%) tobacco users, 11 (25%) alcohol users, 20 (45%) tobacco + alcohol users. Inclusion criteria: histologically confirmed oral leukoplakia. Exclusion criteria: women with reproductive capacity, persons taking megadoses of vitamin A (> 25,000 USP units/day), patients who had had an oral cancer within the 2 years preceding the study. Histological criteria for leukoplakia: not reported. 27% of the lesions were dysplastic.
Interventions
Capsules of placebo or 13-cis-retinoic acid (1 to 2 mg/kg/day), for 3 months. FU since the end of treatment: 6 months. Compliance control: yes.
Outcomes Measurement of the lesion, colour photography, laboratory studies (including fasting serum triglycerides and liver function test) were performed before starting the treatment and every 2 to 3 weeks during treatment. Complete response was defined as no clinical and histological evidence of leukoplakia for at least 4 weeks. Partial response was defined as a greater than 50% reduction in the product of the longest diameters of lesion. A response was classified as stable when the decrease in lesion size was less than 50%. Disease progression was defined as an unequivocal increase in the size of any lesion during treatment or as the appearance of a new lesion. Histological grading was done before starting treatment and upon its completion. Histological grading included: 1 -atypical hyperplasia, 2 -mild dysplasia, 3 -moderate dysplasia, 4 -severe dysplasia or carcinoma in situ. Interventions Systemic (capsules) and topic (paint) placebo or systemic (capsules) and topic (paint) mixed tea (3 g/day and 3 paintings/day), for 6 months. Compliance control: no.
Notes
Risk of bias
Outcomes
Size and number of lesions of each subject were recorded at the baseline and at the end of the trial. Oral biopsies were conducted at the beginning and at the end of the trial. Besides routine histopathological examination lesional tissue investigations included also silver stained nucleolar organizer regions (Ag-NOR), proliferation cell nuclear antigen (PCNA) and epidermal growth factor receptor (EGFR) analysis. A complete regression was defined as the complete disappearance of the lesion. A partial regression was defined as a 30% or more reduction in the size of a single lesion or in the sum of sizes of multiple lesions. Lesions with no change in size were recorded as no change. Deterioration referred to the occurrence of new lesions.
Notes
Risk of bias
Item
Authors' judgement Description
Mulshine 2004
Methods Randomised, parallel-group, double-blind, clinical trial. Moderate risk of bias (unclear methods of allocation, double-blind, 98% of patients who entered the study were included in the final analysis).
Participants 57 patients: 19 females; age not reported; ethnic group: non white subjects: 6/57, white subjects: 51/57; 48/56 (86%) smokers, 40/56 (86%) alcohol users. Inclusion criteria: subjects with bidimensionally measurable leukoplakia of the oral cavity or of the oral pharynx. In case of previous oral cancer diagnosis, individuals had to be free from diseases for at least 3 months, excellent performance status, general good health. Exclusion criteria: hypersensitivity to aspirin, lidocaine, NSAIDs, retinoids. Use of antibiotics, steroids, NSAIDs, aspirin, probenecid, antihistamines for least > 10 consecutive days or any immunosuppressants, anticoagulants, dilantin, lithium, methotrexate, phenothiazines, or drugs that could compromise the test product safety during the 30 days immediately preceding the first treatment visit, debilitating oral conditions requiring extensive dental procedures or conditions interfering with compliance.
Respiratory or cardiovascular problems. Histological criteria for leukoplakia: not reported. Outcomes Measurement and histological assessment of the lesion. Complete response was defined as no clinical and histological evidence of leukoplakia for at least 30 days. Partial response was defined as a greater than 50% reduction in the product of the longest diameters of a single lesion or in the sum of these figures for all lesions, for at least 30 days. A response was classified as stable when the decrease in lesion size was less than 50%. Disease progression was defined as an unequivocal increase in the size greater than 10% or as the appearance of a new lesion. Histological grading was done before starting treatment and upon its completion.
Notes
Data on histological changes were reported partially and did not allow extraction.
In the previous version of the review, this study was included among ongoing studies as Magnuson 2000.
Risk of bias
Item
Authors' judgement Description
Piattelli 1999
Methods Randomised, parallel-group, double-blind, clinical trial. Moderate risk of bias (unclear methods of allocation, double-blind, 90% of patients who entered the study were included in the final analysis). Outcomes Measurement of the lesion, photography, laboratory studies (including serum cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase)were performed before starting the treatment and every month during treatment. A complete response was defined as the complete disappearance of the lesion as assessed by visual inspection, while a partial response was defined as a 50% or more reduction in the size of the lesions.
Notes
At the end of the study period (4 months), patients who received placebo started a 4 months treatment with active medication. Outcomes Details of tobacco and alcohol habits, number, type and dimension of the lesion(s) were recorded at baseline and at each review. Laboratory studies (including estimation of retinol, tocopherols, carotenoids, trace elements, liver and kidney function test) were carried out before starting the treatment and at completion of it. Saliva and urine samples were collected from some of the subjects. Biopsies were taken at baseline and during the study, whenever a malignant transformation was suspected. Complete response was defined as no clinical and histological evidence of leukoplakia for at least 4 weeks. Partial response was defined as a greater than 50% reduction in the size of the single lesion or in the sum of sizes of multiple lesions. Stable and progressive lesions were scored as no response. Malignant transformation was scored if malignancy was histologically established in the lesions during FU. 
Risk of bias
Notes
Risk of bias
Characteristics of ongoing studies [ordered by study ID]
Beenken 2000
Trial name or title Fenretinide in treating patients with leukoplakia of the mouth.
Methods
Participants
Inclusion criteria: (a) histologically proven dysplastic leukoplakia greater than 1 cm in diameter; (b) at least 3 months since prior chronic high dose (greater than 30,000 IU/day) vitamin A (retinol), at least 1 month since other prior retinoids; (c) 18 years and over; (d) WBC at least 3500/mm3, platelet count at least 125,000/ mm3, haemoglobin at least 12.0 g/dL, bilirubin less than 2 times upper limit of normal, creatinine less than 1.7 mg/dL; (e) no symptomatic coronary artery disease, no uncontrolled hypertension, no prior coronary artery bypass, no acute myocardial infarction in the past year; (f ) not pregnant or nursing, negative pregnancy test, fertile patients must use effective barrier contraception for 1 month prior, during and for 12 months after study; (g) fasting serum triglyceride less than 2 times upper limit of normal, cholesterol less than 350 mg/dL; (h) no hypersensitivity to vitamin A or retinoids; (i) no active malignancy, no concurrent acute or chronic medical or psychiatric condition that would preclude compliance or toxicity assessment; (j) no concurrent and severe night blindness.
Interventions
A total of 30 patients will be accrued for this study. Treatment patients receive oral fenretinide daily (except days 1 to 3 each month) for 6 months. Control patients receive oral placebo daily (except days 1 to 3 each month) for 6 months and then receive oral fenretinide daily (except days 1 to 3 each month) for 6 months.
Patients are followed up every 3 months.
Outcomes
Starting date February 2000.
Contact information Notes
Boyle 2000
Trial name or title Celecoxib in treating patients with precancerous lesions of the mouth.
Methods
Participants
Inclusion criteria: (a) histologically confirmed index oral premalignant lesion; (b) at least 3 weeks since prior immunotherapy, chemotherapy, hormonal therapy, chemopreventive therapy; (c) at least 2 weeks since prior beta carotene at 60 mg/day or more, no concurrent beta carotene at 60 mg/day or more, no concurrent oral aspirin greater than 100 mg/day, no other concurrent investigational agents, no concurrent fluconazole or lithium, no concurrent chronic NSAIDs or COX-2 inhibitors; (d) less than 14 days of oral or IV corticosteroid use within the past 6 months, less than 30 days of inhaled corticosteroid use within the past 6 months; (e) at least 3 weeks since prior radiotherapy; (f ) age over 18 and performance status: Zubrod 0 to 1; (g) life expectancy: more than 12 weeks; (h) ematopoietic: haemoglobin greater than lower limit of normal, WBC greater than 3000/mm3, platelet count greater than 125,000/mm3, no significant bleeding disorder; (i) hepatic: bilirubin no greater than 1.5 times upper limit of normal (ULN), AST/ALT no greater than 1.5 times ULN, no chronic or acute hepatic disorder; (j) renal: BUN no greater than 1.5 times ULN, creatinine no greater than 1.5 times ULN, no chronic or acute renal disorder; (k) gastrointestinal: no diagnosis or 
Goodin 2005
Trial name or title A phase II trial to assess the effects of green tea in oral leukoplakia. 
Methods
D A T A A N D A N A L Y S E S
